Overview
TNBC Case Challenges. Test Your Treatment Skills!
Making a Difference in Survival: Integrating New Therapies for Triple-Negative Breast Cancer
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test in these interactive case challenges. As the third and final activity in the TNBC series, you will navigate through two cases. Education is built into the cases, on practical strategies to meet the treatment needs of diverse patients with TNBC.
This activity is intended for medical oncologists, surgical oncologists, oncology nurses, and other healthcare providers who care for patients with TNBC.
TNBC is an aggressive disease that disproportionately affects African American women in the United States. Treatment options are limited for TNBC compared with other types of breast cancer, but new therapies hold promise for improved patient outcomes. Case challenges are presented to help clinician learners integrate the latest TNBC trial data and recommendations. Expert insight from a leading oncologist is also provided within the cases, in guiding treatment decision-making.
Upon completion of this activity, participants will be able to:
-Discuss new targeted treatment approaches in the setting of triple-negative breast cancer
-Discuss the role of antibody-drug conjugate therapies and TROP2 for triple-negative breast cancer
Sponsored by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Supported by an independent educational grant from Gilead Sciences, Inc.
Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine
Chicago, IL
The University of Chicago Pritzker School of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Rita Nanda, MD (Faculty)
Advisory Boards: Aduro, Clovis, Daiichi Sankyo, Fujifilm, Genentech/Roche, Immunomedics, Macrogenics, Merk, Pfizer, Seattle Genetics, GI Therapeutics, AstraZeneca, Celegene, Corcept Therapeutics, OBI Pharma, Odonate Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The University of Chicago Pritzker School of Medicine and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Chicago Pritzker School of Medicine and ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Update as of August 5, 2022: Fam-trastuzumab-deruxtecan-nxki is now approved to treat patients with unresectable or metastatic HER2-low breast cancer.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Ty Jackson at tjackson@achlcme.org.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professional CreditNurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
